Q&A: What is the Impact of Myriad Patent Rulings on IP Landscape for Protein Biomarker-Based Tests? | GenomeWeb

By Adam Bonislawski

Name: Geoff Karny
Position: Principal, Law Office of Geoffrey M. Karny
Background: Vice President, Intellectual Property, Gene Logic; Senior Patent Counsel, Novartis; Senior Intellectual Property Counsel, Genetic Therapy; Attorney, Office of Technology Assessment, United States Congress

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Scripps Research Institute investigators peer back at the RNA world.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.